There were 87 press releases posted in the last 24 hours and 467,037 in the last 365 days.


Please use this form to send email to PR contact of this press release:
VRG Therapeutics demonstrates in vivo efficacy with a selective Kv1.3 inhibitor developed for autoimmune diseases

Zalan Peterfi
VRG Therapeutics


Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image